Search Share Prices
Non-executive director Thomas Casdagli steps away from Alliance Pharma
Specialty pharmaceutical firm Alliance Pharma announced on Wednesday that non-executive director Thomas Casdagli will step down from the board with immediate effect.
The AIM-traded firm said that Casdagli, who is also a partner of MVM Life Science Partners LLP, will be ending a nine year tenure on the company's board.
David Cook, Alliance Pharma's chairman, commented: "On behalf of the board, I would like to thank Tom for his very significant contribution to Alliance over the past nine years. We wish him well for the future."
Casdagli, who is a qualified chartered accountant with an MBioch in Molecular and Cellular Biochemistry from Oxford University, is a member of the boards of Onbone Oy and Patient Connect Ltd.
Furthermore, he was previously a director at Xention Pharma, Lombard Medical Technologies plc, Heptares Ltd and Avantium BV.
Thomas Casdagli said: "It has been a pleasure working with Alliance during my tenure on the board. The company has transformed over this period from a UK-focused established products business to a global pharmaceutical company with good organic and acquisitive growth prospects."
As of 1248 BST, Alliance Pharma's shares were up 0.45% at 89.40p.